PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement, Immuno Cure will use PharmaJet’s Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massachusetts.
The study follows the successful first-in-human ICVAX Phase 1 clinical trial that showed exceptional safety and promising immunogenicity profiles.3 The vaccine represents a significant step towards achieving virological control by ICVAX without antiretroviral therapy and ultimately becoming a functional cure of human immunodeficiency virus (HIV)/AIDS. Immuno Cure is investigating the potential for the Tropis ID system to improve the DNA vaccine performance and patient’s clinical experience.
